Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:03:49 2024-04-25 pm EDT 		5-day change 1st Jan Change
5 USD -1.19% Intraday chart for Black Diamond Therapeutics, Inc. -6.13% +77.05%
Apr. 11 Black Diamond Therapeutics, Inc. Announces Board and Committee Changes CI
Apr. 08 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT

Business Summary

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Number of employees: 54

Managers

Managers TitleAgeSince
Elizabeth Buck FOU
 Founder 49 13-12-31
Mark Velleca CEO
 Chief Executive Officer 60 21-08-08
David Epstein FOU
 Founder 65 13-12-31
Fang Ni DFI
 Director of Finance/CFO 37 20-08-03
Sergey Yurasov CTO
 Chief Tech/Sci/R&D Officer 55 22-05-31
Brent Hatzis-Schoch COO
 Chief Operating Officer 59 19-05-28
Julie Seidel IRC
 Investor Relations Contact - -
Melanie Morrison PRN
 Corporate Officer/Principal - 22-09-30
Elizabeth Montgomery HRO
 Human Resources Officer 52 22-02-21
Erika Jones AUD
 Comptroller/Controller/Auditor 39 19-09-30

Members of the board

Members of the board TitleAgeSince
David Epstein FOU
 Founder 65 13-12-31
Mark Velleca CEO
 Chief Executive Officer 60 21-08-08
Ali Behbahani BRD
 Director/Board Member 47 18-11-30
Garry Menzel BRD
 Director/Board Member 59 13-12-31
Kapil Dhingra BRD
 Director/Board Member 64 21-01-18
Samarth Kulkarni BRD
 Director/Board Member 45 19-11-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,717,849 50,370,610 ( 97.40 %) 0 97.40 %

Shareholders

NameEquities%Valuation
Bellevue Asset Management AG
16.50 %
8,535,839 16.50 % 43 M $
T. Rowe Price Investment Management, Inc.
12.91 %
6,675,756 12.91 % 34 M $
Versant Venture Management LLC
12.43 %
6,428,564 12.43 % 33 M $
NEA Management Co. LLC
8.602 %
4,448,757 8.602 % 23 M $
T. Rowe Price Investment Management, Inc.
7.595 %
3,927,879 7.595 % 20 M $
RA Capital Management LP
6.817 %
3,525,754 6.817 % 18 M $
Artal Group SA
3.957 %
2,046,517 3.957 % 10 M $
Vanguard Global Advisers LLC
3.765 %
1,947,093 3.765 % 10 M $
Tang Capital Management LLC
3.487 %
1,803,200 3.487 % 9 M $
Verition Fund Management LLC
3.006 %
1,554,629 3.006 % 8 M $

Company contact information

Black Diamond Therapeutics, Inc.

One Main Street 14th floor

02142, Cambridge

+

http://www.blackdiamondtherapeutics.com
address Black Diamond Therapeutics, Inc.(BDTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.06 USD
Average target price
12.8 USD
Spread / Average Target
+152.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BLACK DIAMOND THERAPEUTICS, INC. Stock Black Diamond Therapeutics, Inc.
+80.07% 266M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.46% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.96% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. Company Black Diamond Therapeutics, Inc.